Winton Group’s Meridian Bioscience Inc VIVO Stock Holding History

Winton Group’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-74,675	Closed	-$2.48M	–	1099
2022 Q4	$2.48M	Buy	74,675 +11,911	+19%	+$384K	0.16%	156
2022 Q3	$1.98M	Buy	62,764 +47,679	+316%	+$1.54M	0.13%	208
2022 Q2	$459K	Buy	+15,085	New	+$408K	0.02%	711
2021 Q1	–	Sell	-11,015	Closed	-$206K	–	1469
2020 Q4	$206K	Buy	+11,015	New	+$206K	0.01%	1186
2020 Q2	–	Sell	-202,869	Closed	-$1.7M	–	1630
2020 Q1	$1.7M	Buy	202,869 +80,768	+66%	+$680K	0.05%	629
2019 Q4	$1.19M	Buy	122,101 +72,890	+148%	+$684K	0.02%	997
2019 Q3	$467K	Buy	49,211 +20,925	+74%	+$221K	0.01%	1115
2019 Q2	$336K	Buy	+28,286	New	+$341K	0.01%	848
2019 Q1	–	Sell	-214,511	Closed	-$3.72M	–	1217
2018 Q4	$3.72M	Buy	+214,511	New	+$3.66M	0.08%	277

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Winton Group's VIVO Position: Q1 2023 in Review

Winton Group sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 74,675 shares — an estimated $2.48M sold.

Winton Group first reported a position in VIVO in Q4 2018 and held it in 9 quarters. The position peaked at $3.72M in Q4 2018. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Winton Group reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Winton Group sold 74,675 Meridian Bioscience Inc shares in Q1 2023, an estimated $2.48M.
Winton Group first reported a position in Meridian Bioscience Inc in Q4 2018 and held it in 9 quarters.
Winton Group's Meridian Bioscience Inc position peaked at $3.72M in Q4 2018.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Winton Group's 13F filing for Q1 2023, filed 12 May 2023.